https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » Massachusetts
Jazz Pharmaceuticals acquires Cavion, developer of essential tremor drugs

Jazz Pharmaceuticals acquires Cavion, developer of essential tremor drugs

Jazz Pharmaceuticals acquisition of Cavion : Irish pharma company Jazz Pharmaceuticals has acquired US-based clinical-stage pharma company Cavion, a developer of essential tremor drugs, in a deal worth up to $312.5 million as per the latest pharma acquisition news. Based in Cambridge, Massachusetts, Cavion is engaged in developing therapies aimed at regulating the T-type calcium […]

PureTech Health acquires LYT-100 for lymphedema treatment

US biopharma company PureTech Health has acquired a clinical-stage product candidate called LYT-100, which will be developed as the potential treatment of lymphedema, and other lymphatic and immunofibrotic diseases, as per the latest pharma acquisition news. The seller of LYT-100 and the financial terms of the acquisition were not disclosed by PureTech Health. The drug […]

Continue reading …
Pfizer opens $200m biologics clinical manufacturing facility in Andover, MA

US pharma giant Pfizer has opened Andover Clinical Manufacturing Facility (ACMF), a new 175,000sft biologics clinical manufacturing facility built with an investment of over $200 million in Andover, Massachusetts. The biologics clinical manufacturing facility will be used for the development and production of complex biologics and vaccines and is expected to expand Pfizer’s BioTherapeutics Pharmaceutical […]

Continue reading …
X4 Pharmaceuticals wraps up merger with Arsanis

X4 Pharmaceuticals has completed its previously announced merger with Arsanis in a move to create a late-stage biopharma company focused on rare diseases and cancer. Both companies are based in Massachusetts. X4 Pharmaceuticals is engaged in developing drugs designed to boost immune cell trafficking for the treatment of rare diseases that include primary immunodeficiencies and […]

Continue reading …
Blackstone Life Sciences, Novartis launch Anthos Therapeutics

Blackstone Life Sciences, a private investment platform, has joined forces with Swiss drug maker Novartis to launch a new biopharma company called Anthos Therapeutics, which will focus on developing drugs for high-risk cardiovascular patients. Anthos Therapeutics, which will be headquartered in Cambridge, Massachusetts, is backed by a capital of $250 million from Blackstone Life Sciences. […]

Continue reading …
Merck’s EMD Serono to expand biopharma R&D facility with $70m investment

German pharma company Merck will invest $70 million for the expansion of its US and Canada biopharma business EMD Serono’s research and development (R&D) facility in Billerica, Massachusetts. The expansion of the R&D facility through the addition of a new building is expected to enable drug discoveries in the areas of oncology, immuno-oncology and immunology. […]

Continue reading …
Pulmatrix secures FDA approval for Pulmazole phase 2 clinical study

Pulmazole phase 2 clinical study : Pulmatrix said that the US Food and Drug Administration (FDA) has authorized the Massachusetts-based biopharma company to begin a phase 2 clinical trial for Pulmazole (PUR1900), for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. This was after the US drug regulator completed its review of […]

Continue reading …
GSK wraps up $5.1bn acquisition of US cancer drug company Tesaro

GSK acquisition of Tesaro : British pharma giant GlaxoSmithKline (GSK) has completed its previously announced $5.1 billion acquisition of Tesaro, an oncology-focused biopharma company based in Waltham, Massachusetts. The acquisition of Tesaro is expected to help GSK reinforce its pharmaceutical business and expand its pipeline and commercial capability in oncology. The two companies entered into […]

Continue reading …